0001626199-23-000081.txt : 20230614 0001626199-23-000081.hdr.sgml : 20230614 20230614160643 ACCESSION NUMBER: 0001626199-23-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230613 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 231014151 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 8-K 1 alpn-20230613.htm 8-K alpn-20230613
0001626199false00016261992023-06-132023-06-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2023
  
ALPINE IMMUNE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-37449 20-8969493
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
188 East Blaine Street, Suite 200
Seattle, Washington 98102
(Address of principal executive offices, including zip code)
(206788-4545
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol  Name of each exchange on which registered
Common Stock, par value $0.001 per shareALPNThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 5.07. Submission of Matters to a Vote of Security Holders.
On Tuesday, June 13, 2023, Alpine Immune Sciences, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) at 1:30 p.m., Pacific Time, as a web-hosted, virtual meeting. As of the close of business on April 20, 2023, the record date for the 2023 Annual Meeting, there were 47,965,835 shares of common stock entitled to vote at the meeting. 41,461,920 shares of common stock were present in person or by proxy at the meeting (86.44%), which constituted a quorum for the transaction of business.

At the 2023 Annual Meeting, the stockholders voted on the following four proposals, each of which is described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 27, 2023 (the “Proxy Statement”). The matters voted upon and the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, as to each such matter were as follows:
Proposal 1. Election of Directors

The stockholders voted on a proposal to elect three Class II directors to the Company’s board of directors (the “Board”), each to serve a three-year term. The results of the voting were as follows:
NomineeVotes ForVotes WithheldBroker Non-Votes
Mitchell H. Gold, M.D.39,359,956161,6131,940,351
Xiangmin Cui, Ph.D.34,802,3254,719,2441,940,351
Jörn Drappa, M.D., Ph.D.39,501,91419,6551,940,351
Pursuant to the foregoing votes, each of the director nominees was elected to serve on the Board. There were no additional director nominations brought to the 2023 Annual Meeting.
Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm
The stockholders voted on a proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The results of the voting included 41,447,816 votes for, 3,654 votes against, 10,450 votes abstained and no broker non-votes. The appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was ratified.
Proposal 3. Advisory Vote on Compensation of Named Executive Officers (Say-On-Pay)
The stockholders voted on a proposal for the approval, on an advisory basis, of the compensation of the Company's named executive officers. The results of the voting included 39,290,103 votes for, 203,623 votes against, 27,843 votes abstained and 1,940,351 broker non-votes. The compensation of the Company's named executive officers was approved, on an advisory basis.
Proposal 4. Amendment and Restatement of the Amended and Restated Certificate of Incorporation, as Amended
The stockholders voted on a proposal for the amendment and restatement of the Company's amended and restated certificate of incorporation, as amended, to limit the liability of certain officers of the Company as permitted by Delaware law. The results of the voting included 38,004,875 votes for, 1,339,148 votes against, 177,546 votes abstained and 1,940,351 broker non-votes. The amendment and restatement of the amended and restated certificate of incorporation, as amended, was affirmed. A conformed copy of the amended and restated certificate of incorporation that was filed with the Secretary of State of the State of Delaware is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.




Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.Description
3.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: June 14, 2023  ALPINE IMMUNE SCIENCES, INC.
 By: /s/ Paul Rickey
 Name: Paul Rickey
 Title: Senior Vice President and Chief Financial Officer


EX-3.1 2 ex31-amendedandrestatedcer.htm EX-3.1 Document
Exhibit 3.1
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
ALPINE IMMUNE SCIENCES, INC.
(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)
Alpine Immune Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, as amended (the “DGCL”), hereby certifies as follows:
DOES HEREBY CERTIFY:
1.    The name of the Corporation is Alpine Immune Sciences, Inc. The predecessor to the Corporation, N30 Pharmaceuticals, LLC, was originally formed as a limited liability company under Section 18-201 of the Delaware Limited Liability Company Act on March 30, 2007. Effective as of 12:01 a.m. Eastern Standard Time on August 1, 2012, the Corporation’s predecessor was converted into a Delaware corporation pursuant to a Certificate of Conversion filed with the Delaware Secretary of State on July 31, 2012. The Corporation’s original Certificate of Incorporation was filed with the Delaware Secretary of State on July 31, 2012 under the name N30 Pharmaceuticals, Inc. On February 11, 2015, the Corporation changed its name from N30 Pharmaceuticals, Inc. to Nivalis Therapeutics, Inc. On July 24, 2017, the Corporation changed its name from Nivalis Therapeutics, Inc. to Alpine Immune Sciences, Inc.
2.    This Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”) amends and restates the Corporation’s Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on June 22, 2015, as amended (the “Prior Certificate”), and has been duly adopted in accordance with the provisions of Sections 242 and 245 of the DGCL.
3.    The text of the Prior Certificate is hereby amended and restated in its entirety to read as set forth in Exhibit A attached hereto.
IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this Corporation on this 13th day of June, 2023.
By:    /s/ Mitchell H. Gold    
Mitchell H. Gold, M.D., Chief Executive Officer




EXHIBIT A
ARTICLE I
The name of this Corporation is Alpine Immune Sciences, Inc.
ARTICLE II
The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such address is Corporation Service Company.
ARTICLE III
The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the DGCL.
ARTICLE IV
A.    The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 200,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”), and (ii) 10,000,000 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).
B.    The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the “Board”) is hereby expressly authorized, by filing a certificate (“Certificate of Designation”) pursuant to the DGCL, to provide for the issue of any or all of the unissued and undesignated shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences and relative, participating, optional, or other rights and such qualifications, limitations or restrictions thereof as shall be stated and expressed in the resolution or resolutions adopted by the Board providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock.
C.    Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (this “Certificate of Incorporation”) (including any Certificate of Designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other series of Preferred Stock, to vote thereon by law or pursuant to this Certificate of Incorporation (including any Certificate of Designation filed with respect to any series of Preferred Stock).
ARTICLE V
In furtherance and not in limitation of the powers conferred by the DGCL, subject to the rights of the holders of any series of Preferred Stock that may be designated from time to time, the Board is expressly authorized to adopt, amend or repeal the bylaws of the Corporation (the “Bylaws”), subject to the power of the stockholders of the Corporation to alter or repeal any Bylaws whether adopted by them or otherwise; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation (including any Certificate of Designation that may be filed from time to time), the affirmative vote of holders of not less than sixty-six and two-thirds percent (66 2/3%) of the votes of all outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class, shall be required for the stockholders to adopt new Bylaws or to alter, amend or repeal the Bylaws.
2


ARTICLE VI
A.    The management of the business and the conduct of the affairs of the Corporation shall be vested in the Board. The number of directors which shall constitute the whole Board shall be fixed exclusively by one or more resolutions adopted from time to time by the Board.
B.    The directors shall be divided into three classes, designated as Class I, Class II and Class III, as nearly equal in number as possible. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board. At each annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. Notwithstanding the foregoing provisions of this Article VI.B., each director shall serve until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board shall shorten the term of any incumbent director.
C.    The Board or any individual director may be removed from office only for cause at a meeting of stockholders called for that purpose, by the affirmative vote of the holders of at least at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all the then outstanding shares of voting stock of the Corporation entitled to vote at an election of directors, voting together as a single class.
D.    Any vacancies on the Board resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law and or by this Certificate of Incorporation or any Certificate of Designation that may be filed with respect to a series of Preferred Stock, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified.
E.    The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.
F.    There shall be no cumulative voting in the election of directors.
ARTICLE VII
A.    Subject to the rights of the holders of any series of Preferred Stock or any other class of stock or series thereof having a preference over the Common Stock as to dividends or upon liquidation, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders of the Corporation. The taking of any action by written consent of the stockholders in lieu of a meeting of the stockholders is specifically denied.
B.    Special meetings of the stockholders of the Corporation may be called, for any purpose or purposes, by the Secretary of the Corporation at the direction of the Board, pursuant to a resolution adopted by a majority of the entire Board, but such special meetings may not be called by any other person or persons.
C.    Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.
ARTICLE VIII
A.    To the fullest extent permitted by the DGCL, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL is amended after approval by the stockholders of this Article VIII to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.
B.    Any repeal, amendment, elimination or modification of the foregoing provisions of this Article VIII shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of, or increase the liability of any director or officer of the Corporation with respect to any acts or omissions of such director or officer occurring prior to, such repeal, amendment, elimination or modification.
3


ARTICLE IX
Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or the Corporation’s stockholders, (c) any action asserting a claim arising pursuant to any provision of the DGCL, this Certificate of Incorporation or the Bylaws, or (d) any action asserting a claim that is governed by the internal affairs doctrine, in each such case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of the Corporation’s capital stock shall be deemed to have notice of, and to have consented to the provisions of this Article IX.
ARTICLE X
Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Corporation required by law or by this Certificate of Incorporation or any Certificate of Designation that may be filed with respect to a series of Preferred Stock, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all of the then-outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles VI, VII, VIII, IX and this Article X.
* * *
4
EX-101.SCH 3 alpn-20230613.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 alpn-20230613_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 alpn-20230613_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page
Jun. 13, 2023
Cover [Abstract]  
Entity Central Index Key 0001626199
Amendment Flag false
Document Type 8-K
Document Period End Date Jun. 13, 2023
Entity Registrant Name ALPINE IMMUNE SCIENCES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37449
Entity Tax Identification Number 20-8969493
Entity Address, Address Line One 188 East Blaine Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code 206
Local Phone Number 788-4545
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALPN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 alpn-20230613_htm.xml IDEA: XBRL DOCUMENT 0001626199 2023-06-13 2023-06-13 0001626199 false 8-K 2023-06-13 ALPINE IMMUNE SCIENCES, INC. DE 001-37449 20-8969493 188 East Blaine Street Suite 200 Seattle WA 98102 206 788-4545 false false false false Common Stock, par value $0.001 per share ALPN NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -6 SE8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #5@,Y6K/X]N>X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R'%*#B;-I6.G#08K;.QF;+4UB_]@:R1]^R59FS*V!]C1TL^? M/H%:':4."9]3B)C(8KX;7>^SU''+3D11 F1]0J=R.27\U#R$Y!1-SW2$J/2' M.B((SAMP2,HH4C #B[@26=<:+75"12%=\$:O^/B9^@5F-&"/#CUEJ,H*6#=/ MC.>Q;^$&F&&$R>7O IJ5N%3_Q"X=8)?DF.V:&H:A'.HE-^U0P=O3X\NR;F%] M)N4U3K^RE72.N&77R:_U[G[_P#K!15WPIJ@V>\$E;^1&O,^N/_QNPBX8>[#_ MV/@JV+7PZRZZ+U!+ P04 " #5@,Y6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M -6 SE82!HO6: 0 "P1 8 >&PO=V]R:W-H965T&UL MC9AA;^HV%(;_BI5-TR:U)0Z40@=(E-*-W9;+&NXJ;=H'DQBP;F)GME/:?[_C M0!-V%T[XT"9.,G.E,B[A MSEKIE%EHZDW+9)JSN A*DU;@^]U6RH3T1H/BVD*/!BJWB9!\H8G)TY3I]SN> MJ-W0H]['A6>QV5IWH34:9&S#0VZ_9 L-K5:I$HN42R.4))JOA]Z8WMX%URZ@ M>.(/P7?FZ)RXKJR4^NH:LWCH^8Z()SRR3H+!X95/>)(X)>#XYR#JE>]T@>A,RMF^$0E+R*VVZ'7\TC,URQ/[+/:__^B@O*>638::+4CVCT-:NZDZ&H1 M#7!"NED)K8:[ N+L:*)>N28+F(!!RX*>N]J*#K%W^]C@1.QON;PBM'U! C]H M_S>\!1@E2U"R!(5>&V7Y:[PR5L-L_5U'M%?HU"NX%+XU&8OXT(,<-5R_TZ_^,\+5+OC:F/II**^P[F7 )? F9R9B_D4_\O8X35_)]GW:#+NWW$:Q. MB=5!Q<:P2&+XL^0A89LZ&#Q^S1+#$8[KDN,:U;E745Y@+-^SVFS"PWN7GQ"( M;@G1/0]BP;50,9G*F,#"J.7!E>8;X1(<&..9@S&2F=*5Z0T,(@$J7) M1.60_K *5%S+CHO?3Q'"?DG8/X?P022#$M6!U+-5.UL+A2FU[OL7'>N,:*J(%#7! MV4PM%2[4M-.@506@N'V'*A&1L$)NR!.DMQ8LJ>7!59IX@JH !+A;+S2_C&!X M.*RO_1X(]F2PF?V\7M?/7X->(UEE_ 'NTO\CFQF3 UDC("[;"'BTZ<>->2G M^8A:$QK\N/J)A#S*(=]J-]4-2BX_H>2&5D5?+TC&-'EE2<[)]_X5E'N207?- MEFD4NZH 6[92\UBEW[A>[I2MXX,E\:QU]^[K?$9Z8 M>Z,A"5^#D']U [IZ_VF^;UB5%9_#*V7AX[HXW7(&:\$] /?72MF/AOO"+G\@ M&?T+4$L#!!0 ( -6 SE:?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0& M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&- M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+ MY2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'D ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^ M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM! M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7 M,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( -6 SE:7BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.alpineimmunesciences.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports alpn-20230613.htm alpn-20230613.xsd alpn-20230613_lab.xml alpn-20230613_pre.xml ex31-amendedandrestatedcer.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alpn-20230613.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "alpn-20230613.htm" ] }, "labelLink": { "local": [ "alpn-20230613_lab.xml" ] }, "presentationLink": { "local": [ "alpn-20230613_pre.xml" ] }, "schema": { "local": [ "alpn-20230613.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alpn", "nsuri": "http://www.alpineimmunesciences.com/20230613", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alpn-20230613.htm", "contextRef": "i9de09d40e144405c9f0729b18ec3086a_D20230613-20230613", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.alpineimmunesciences.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alpn-20230613.htm", "contextRef": "i9de09d40e144405c9f0729b18ec3086a_D20230613-20230613", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001626199-23-000081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001626199-23-000081-xbrl.zip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